DHL acquires CRYOPDP, enters strategic partnership with Cryoport

Investing.com -- DHL Group, the world’s foremost logistics provider, has acquired 100% of CRYOPDP, a specialty courier with a focus on clinical trials, biopharma, and cell and gene therapies. In addition, DHL and Cryoport, Inc. (NASDAQ: CYRX), a global life sciences supply chain solutions provider, have announced a strategic partnership to bolster their supply chain services for the worldwide life sciences and healthcare sector.

DHL’s Life Sciences and Healthcare business contributed over EUR 5 billion to global revenue in 2024. The acquisition of CRYOPDP represents a significant move in DHL’s commitment to boost its specialized pharma logistics capabilities and broaden its services in the rapidly expanding life science and healthcare sector.

CRYOPDP, operating in 15 countries, handles over 600,000 shipments annually, serving customers and patients in over 135 countries worldwide. DHL Supply Chain will leverage the specialty courier expertise of CRYOPDP and the global air capabilities of DHL Express and DHL Global Forwarding to enhance its Pharma Specialized Network solution.

The strategic partnership with Cryoport will combine DHL’s global health logistics capabilities with Cryoport’s industry-leading expertise in providing specialized solutions in a fast-growing life science and healthcare market segment. This partnership will also deepen DHL’s relationship with all the Cryoport business units concerning specialized pharma.

“The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment," Oscar de Bok, CEO of DHL Supply Chain, stated. He added that the acquisition and the extended partnership with Cryoport Inc (NASDAQ:CYRX). will enhance DHL’s ability to deliver integrated end-to-end solutions.

Jerrell Shelton, CEO of Cryoport, sees the strategic partnership as a substantial opportunity for Cryoport to further expand its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).

The acquisition aligns with DHL Group’s Strategy 2030, which emphasizes the importance of temperature-controlled networks, first and last mile specialty courier coverage, and integrated solutions. CRYOPDP’s capabilities will be instrumental in achieving these objectives and help position DHL as a leader in providing comprehensive solutions for the pharma industry. This move is also expected to yield cost savings and improve overall service levels, particularly leveraging DHL Express and DHL Global Forwarding air capabilities, ultimately enhancing DHL’s footprint in the high-value advanced pharma sector.

For Cryoport, the partnership will allow it to better execute its business in EMEA and APAC with a stronger focus on its core business in these regions, creating even greater opportunities to offer top-tier services in answering market demand for its services and products.

The deal and the outlined partnership are subject to regulatory approvals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.